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Abstract. Non-small cell lung cancer (NSCLC) is the most 
deadly type of cancer worldwide. Although a number of 
therapies are used in NSCLC treatment, their therapeutic 
efficacy remains low. Lenalidomide was originally approved 
for use in patients with myelodysplastic syndromes, which 
are associated with 5q deletions, and multiple myeloma. 
Recently, lenalidomide was investigated as a new NSCLC 
treatment, and it exerted anticancer effects. However, the 
primary cellular mechanism of its effects in NSCLC is 
largely unknown. Therefore, we attempted to elucidate a 
molecular portrait of lenalidomide-mediated cellular events 
in NSCLC. Lenalidomide reduced the viability of several 
NSCLC cell lines in a concentration-dependent manner. In 
addition, array-based gene expression analysis revealed that 
lenalidomide regulated the expression of several genes associ-
ated with cell survival, apoptosis and development, including 
BH3-interacting domain death agonist (BID), v-fos FBJ 
murine osteosarcoma viral oncogene homolog (FOS) and NK2 
homeobox1 (NKX2-1). BID and FOS, which are known apop-
tosis activators, were upregulated by lenalidomide treatment, 
whereas NKX2-1, which is used as an immunohistochemistry 
marker for NSCLC, was downregulated. These results provide 
evidence that lenalidomide directly induces antiproliferative 
effects by altering the expression of genes associated with cell 
proliferation and apoptosis. 
Introduction
Lung cancer is one of the most common types of cancer and 
it remains the leading cause of cancer mortality in males 
and females worldwide. There are two major types of lung 
cancer: small cell lung cancer and non-small cell lung cancer 
(NSCLC) (1,2). NSCLC, which is the most common type of 
lung cancer, has a low 5-year survival rate (<15%), a poor 
prognosis and a high rate of relapse (3). At present, various 
chemotherapies, including combination therapies and targeted 
therapies, have been utilized to treat NSCLC; however, 
the efficacy of these therapies is insufficient. Therefore, the 
development of other therapies against NSCLC progression is 
required for improving the efficacy of cancer treatment.
As a novel therapeutic strategy, immunomodulatory drugs 
have been utilized to treat NSCLC. The immunomodulatory 
drug lenalidomide was originally approved to treat myelo-
dysplastic syndromes and multiple myeloma (4,5). However, 
lenalidomide has been investigated for treating other types 
of cancer, including NSCLC, malignant melanoma and 
prostate cancer (6-11). Lenalidomide has been reported to 
alter the production of cytokines and growth factors, which 
in turn enhances the immune response against tumor cells 
and inhibits tumor angiogenesis (12,13). Moreover, it has been 
reported that lenalidomide is a potent co-stimulator of T-cell 
activation, leading to increased T-cell cytokine production and 
activation of CD8+ T cells and NK cells (14,15). Furthermore, 
lenalidomide has direct antiproliferative effects on tumor cells 
in the absence of immune effector cells (16). Lenalidomide 
causes concentration-dependent cell cycle arrest in G0-G1 
phase by upregulating the CDK inhibitor p21 waf-1, a key cell 
cycle regulator that modulates the activity of CDKs, and down-
regulating the activities of the prosurvival kinases ERK1/2 and 
Akt (17,18). Lenalidomide inhibits the translation of C/EBPβ 
by downregulating eIF4E, and IRF4 downregulation has been 
reported to be a critical factor controlling multiple myeloma 
survival and as a prognostic marker in patients with multiple 
myeloma associated with poor survival (19,20). In NSCLC, 
objective responses have been observed with lenalidomide-
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based therapy, suggesting that lenalidomide is a potent drug for 
NSCLC treatment. Despite the clinical effects of lenalidomide, 
studies of the precise mechanisms of its action in NSCLC have 
not yet been performed. Studies of the mechanisms of the anti-
cancer properties of lenalidomide are critical for improving 
the efficacy of this drug against NSCLC. In the present study, 
we investigated the antiproliferative activity of lenalidomide 
against NSCLC cell lines and the gene expression profile 
changes in lenalidomide-treated NSCLC cells. 
Materials and methods
Cell culture and lenalidomide treatment. The human 
NSCLC cell lines Lu-99, H1299, A549, EBC1 and H460 were 
purchased from the ATCC (Manassas, VA, USA) and cultured 
in RPMI-1640 medium containing 10% fetal bovine serum 
and antibiotics at 37˚C in a humidified chamber containing 5% 
CO2. Cells were seeded into 60-mm culture dishes (2x105 cells 
per dish) with various concentrations of lenalidomide (Celgene, 
Summit, NJ, USA) and incubated for various times. 
RNA preparation and cDNA synthesis. Following lenalido-
mide treatment, total RNA was extracted from cells using 
TRIzol reagent (Invitrogen, Carlsbad, CA, USA) according 
to the manufacturer's instructions. For the microarray studies, 
both the quality and concentration of the RNA samples were 
determined using an Agilent 2100 Bioanalyzer (Agilent 
Technologies, Santa Clara, CA, USA) and a MaestroNano 
Spectrophotometer (Maestrogen, Las Vegas, NV, USA). 
The recommended RNA quality parameters for microarray 
analysis are as follows: UV spectroscopy A260/A280 ratio of 
1.8-2.0 and an A260/A230 ratio >1.8; an 18S/28S rRNA ratio 
of 1.8-2.1; and an RNA integrity number >8.0. To synthesize 
cDNA, 1 µg RNA was incubated with oligo dT primers at 94˚C 
for 10 min and reverse transcribed with reverse transcriptase 
(Enzynomics, Seoul, Korea) at 37˚C for 1 h. 
DNA microarray analysis. DNA microarray analysis was 
performed using a HumanHT-12 v4.0 Expression Beadchip 
kit (Illumina, San Diego, CA, USA) according to the manu-
facturer's instructions. The derived data were analyzed using 
Genespring GX 11 (Agilent Technologies). The raw data were 
filtered using the flag test and t-test, therefore the miRNAs 
showing detectable expression levels (flag value = present) were 
selected, and subjected to fold-change analysis. Significant 
genes were determined using the fluorescence ratio between the 
control and lenalidomide-treated samples, and genes displaying 
a >2-fold increase or decrease were selected for analysis. 
Polymerase chain reaction (PCR) analysis. The expression 
levels of BH3-interacting domain death agonist (BID), v-fos 
FBJ murine osteosarcoma viral oncogene homolog (FOS) and 
NK2 homeobox1 (NKX2-1) mRNA were determined by PCR 
with their specific primers as follows: GADPH, (F) 
5'-TTGCCATCAATGACCCCTTCA-3' and (R) 5'-CGC 
CCCACTTGATTTTGGA-3'; BID, (F) 5'-ATGGAC 
TGTGAGGTCAACAACGG-3' and (R) 5'-CACGTA 
GGTGCGTAGGTTCTGGTTA-3'; Fos, (F) 5'-CCAACT 
TCATTCCCACGGTCAC-3'  and (R) 5'-TGGCAA 
TCTCGGTCTGCAAA-3'; NKX2-1, (F) 5'-ATGTCG 
ATGAGTCCAAAGCA-3' and (R) 5'-ACCG TATAGCA 
AGGTGGAGCA-3'.
Cell viability assay. Cell proliferation was determined using 
the WST-1 assay (EZ-Cytox Cell Viability Assay kit, ITSBIO, 
Seoul, Korea) according to the manufacturer's instructions. 
In brief, cells were incubated in 96-well plates and treated 
with DMSO or various concentrations of lenalidomide in 
RPMI-1640 medium containing 10% FBS for 2 or 3 days. 
After incubation, the kit solution was added to the cultured 
cells, which were incubated at 37˚C for 2 h. Cell viability 
was measured using an iMark microplate reader (Bio-Rad, 
Hercules, CA, USA) at 450 nm using a 620-nm reference filter.
Statistical analysis. Statistical analysis was performed using 
the χ2 test or Fisher's exact test and Spearman rank correla-
tion coefficient analysis. P<0.05 was considered to indicate a 
statistically significant result.
Results and Discussion
We first examined whether the immunomodulatory drug 
lenalidomide exhibited direct antitumor activity in NSCLC cell 
lines. To this end, Lu-99, H1299, H460, EBC1 and A549 cells 
were exposed to a series of increasing concentrations of lenalid-
omide for 72 h and the proliferation of the cells was measured 
by analyzing the activity of mitochondrial dehydrogenases 
using the WST-1 assay (described in Materials and methods). 
The assays revealed that lenalidomide significantly inhibited the 
proliferation of NSCLC cells (Lu-99, H1299, H460 and A549) in 
a concentration-dependent manner (Fig. 1). In particular, H460 
cells had the highest sensitivity for lenalidomide, and therefore, 
we used this cell line to perform the subsequent experiments.
We next performed gene expression profiling analysis to 
gain insight into the mode of action of lenalidomide and to iden-
tify the molecular targets of this drug. H460 cells were treated 
with the control DMSO or 10 µM lenalidomide for 72 h and 
RNA samples were purified. The quality of each sample was 
confirmed using Agilent software. We then compared the gene 
expression profiles of the lenalidomide- and DMSO-treated 
samples (see Materials and methods). As shown in Fig. 2A, 
lenalidomide regulated the transcription of genes, and the 
genes displaying >1.5-fold changes in transcription compared 
with that in control cells were selected and identified by color 
contrast. Notably, 3-fold more mRNAs were downregulated 
(474 mRNAs) than upregulated (158 mRNAs) by lenalidomide 
treatment in H460 cells, indicating that lenalidomide has an 
inhibitory effect on gene transcription. To further analyze the 
transcriptional effect of lenalidomide, the 50 genes most strongly 
affected by lenalidomide treatment were selected, as shown in 
Table Ι. Furthermore, using the bioinformatics tool of Gene Set 
Enrichment Analysis (http://www.broadinstitute.org/gsea/index.
jsp), the genes with >1.5-fold changes in expression were catego-
rized into different functional categories, such as homology or 
biochemical activity, using the Gene Ontology project for gene 
sharing (Table II). Specifically, transcription factors, tumor 
suppressors and oncogenes were relatively more abundant than 
other biological function-related genes in Table ΙΙ. 
To verify the microarray data, we performed reverse-tran-
scription PCR (RT-PCR) analysis of several genes selected on 
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the basis of their roles in apoptosis, cell cycle regulation, tran-
scription and oncogenesis in NSCLC cells. These genes were 
BID, FOS and NKX2-1. BID is a member of the proapoptotic 
BCL2 family and is a key component of death receptor-mediated 
caspase activation (21). FOS is a transcription factor that binds to 
Figure 1. Lenalidomide induces the loss of cell viability in NSCLC cell lines. 
Lu-99, H1299, H460, EBC1 and A549 cells were treated with a series of con-
centrations of lenalidomide for 72 h. The cell viabilities of these cell lines were 
detected by the WST-1 assay. All experiments were performed in triplicate 
(n=3). Statistical significance compared with the findings in control cells for 
each condition was indicated by P<0.05. NSCLC, non-small cell lung cancer.
Table I. Top 50 genes displaying >1.5-fold changes in expres-
sion following lenalidomide treatment.
 Upregulated genes Downregulated genes
-------------------------------------------------- ------------------------------------------------
Gene name FC Gene name FC
C14ORF153 2.92 ZNF121 2.91
GINS4 2.53 NMI 2.01
XRCC2 2.08 OR5T1 1.98
SNN 2.01 ALOX15 1.87
GRIPAP1 1.93 KCNA4 1.84
FKBP14 1.92 ARR3 1.78
BPNT1 1.87 OR11A1 1.78
RBBP9 1.85 HFM1 1.75
BLZF1 1.85 NKX2-1 1.75
HMG1L1 1.81 LOXL1 1.74
QRFPR 1.81 WDR21C 1.74
LMOD3 1.78 PENK 1.73
ZNF483 1.77 CCDC121 1.73
DCDC1 1.77 NOS2A 1.71
SHROOM4 1.77 LONRF3 1.70
DUSP19 1.76 SS18 1.70
ZNF549 1.75 AIM1L 1.69
CHRNAS 1.75 EFCBP1 1.69
DEM1 1.75 KLC3 1.68
USP49 1.74 CSAG3B 1.68
PDP2 1.74 NUCKS1 1.67
ZMAT3 1.74 MORF4L1 1.67
MYO3B 1.74 LY6G5C 1.67
ZNF69 1.73 ESRRG 1.66
OVOS2 1.73 LYPD4 1.66
LRRFIP1 1.72 LRRN3 1.66
TTTY22 1.72 KIF5A 1.66
TRIM13 1.72 FBXO47 1.66
GNB4 1.72 PRDM13 1.65
CCBE1 1.72 SYT15 1.65
ZNF14 1.71 UPK3B 1.65
FOS 1.71 CPM 1.65
IL17RD 1.70 BZW1 1.65
MAGT1 1.70 ASB4 1.64
TDP1 1.67 MEST 1.64
EIB2B 1.67 LGR6 1.63
XCL1 1.67 GEM 1.63
CDKN2A 1.67 MICALL2 1.62
BID 1.66 PCDHGA1 1.62
DDX51 1.65 PCLO 1.62
ARL16 1.63 SYPL2 1.62
AGER 1.63 NR1I2 1.61
NLRP8 1.63 EPHA10 1.61
FUT6 1.61 DGKB 1.61
NSBP1 1.61 GRHL1 1.61
CREB1 1.61 SLC6A5 1.61
CDH24 1.60 MCM9 1.61
DMC1 1.56 RGN 1.61
PHAX 1.53 CDC25B 1.61
MTSS1L 1.51 STATH 1.60
List shows the top 50 genes displaying >1.5-fold changes in expression 
after FLAG sorting. Predicted genes are not shown. FC, fold change.
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Jun and creates the transcription factor activator protein 1, which 
regulates cell proliferation, differentiation and apoptosis (22). 
Although the experimental condition of the microarray was 
based on the single time point (72 h) of lenalidomide treat-
ment, as shown in Fig. 1, RT-PCR was performed to clarify the 
results of the expression levels of BID, FOS and NKX2-1 by 
treating cells with lenalidomide for 24, 48 and 72 h. As shown 
in Fig. 3, the results revealed good concordance in gene expres-
sion between the microarray and RT-PCR data. BID and FOS, 
which were upregulated by lenalidomide in the array data, were 
markedly upregulated in a time-dependent manner; conversely, 
NKX2-1 was downregulated by lenalidomide in the array and 
RT-PCR data. Thus, lenalidomide-induced antiproliferative 
effects may be mediated by regulating the expression of genes 
associated with apoptosis, cell survival and transcription factors.
In NSCLC, the NKX2-1 (also known as TTF1) gene is an 
immunohistochemical marker for predicting the adenocarci-
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Figure 2. Lenalidomide causes changes in the gene expression profiles of 
NSCLC cells. (A) Genes that displayed >2-fold changes in expression fol-
lowing lenalidomide treatment compared with their expression in control 
cells. Genes upregulated by lenalidomide are presented on the left and genes 
downregulated by lenalidomide are presented on the right. (B) The num-
bers of genes up- and downregulated by lenalidomide treatment. NSCLC, 
non-small cell lung cancer.
  A
  B
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noma subtype (23,24). The NKX2-1 gene is amplified in 10-15% 
of lung adenocarcinomas, and results of in vitro studies further 
support the hypothesis that NKX2-1 acts as a lineage-specific 
oncogene (24,25). However, a tumor suppressor role has been 
observed in the same type of cancer for NKX2-1 (26). The 
expression of exogenous NKX2-1 limited tumor progression, 
resulting in fewer tumors with an advanced histopathological 
grade. Therefore, NKX2-1 has both oncogenic and tumor-
suppressive functions in lung cancer, suggesting that NKX2-1 
downregulation following lenalidomide treatment in NSCLC 
cells is a meaningful result that requires further investigation.
These findings further the knowledge of the signaling path-
ways targeted by lenalidomide and suggest that lenalidomide 
causes changes in the gene expression profile of NSCLC cells. 
In addition, these genes may be prospective target molecules 
for the mechanism involved in the lenalidomide-induced anti-
proliferative effect in NSCLC cells.
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